Polymyositis and dermatomyositis: Novel insights into the pathogenesis and potential therapeutic targets

Discovery Medicine

Volumn 19, Issue 107, 2015, Pages 463-470

  Lahouti, Arash H ^a   Christopher Stine, Lisa ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BELIMUMAB; BORTEZOMIB; CYTOKINE; INTERLEUKIN 15; MYOSITIS SPECIFIC AUTOANTIBODY; SIFALIMUMAB; TOCILIZUMAB; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; B LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; DERMATOMYOSITIS; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; MUSCLE BIOPSY; MUSCLE INJURY; NECROSIS; PATHOGENESIS; POLYMYOSITIS; T LYMPHOCYTE; AUTOIMMUNE DISEASES; CELLULAR IMMUNITY; IMMUNOLOGY; PATHOLOGY; SKELETAL MUSCLE;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; HUMANS; IMMUNITY, CELLULAR; MUSCLE, SKELETAL; T-LYMPHOCYTES;

EID: 84940474099     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406(6797):782-787, 2000.
2. Aggarwal R, Oddis CV. Therapeutic advances in myositis. Curr Opin Rheumatol 24(6):635-641, 2012.
3. Albayda J, Christopher-Stine L. Novel approaches in the treatment of myositis and myopathies. Ther Adv Musculoskelet Dis 4(5):369-377, 2012.
4. Alger HM, Raben N, Pistilli E, Francia DL, Rawat R, Getnet D, Ghimbovschi S, Chen YW, Lundberg IE, Nagaraju K. The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum 63(11):3448-3457, 2011.
5. Baek A, Park HJ, Na SJ, Shim DS, Moon JS, Yang Y, Choi YC. The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol 249(1-2):96-100, 2012.
6. Baird GS, Montine TJ. Multiplex immunoassay analysis of cytokines in idiopathic inflammatory myopathy. Arch Pathol Lab Med 132(2):232-238, 2008.
7. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48(11):3253-3265, 2003.
8. Bilgic H, Ytterberg SR, Amin S, Mcnallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60(11):3436-3446, 2009.
9. Bradshaw EM, Orihuela A, Mcardel SL, Salajegheh M, Amato AA, Hafler DA, Greenberg SA, O'connor KC. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 178(1):547-556, 2007.
10. Brunn A, Zornbach K, Hans VH, Haupt WF, Deckert M. Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 71(10):855-867, 2012.
11. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ. Down-regulation of CD28 expression by TNF-alpha. J Immunol 167(6):3231-3238, 2001.
12. Cappelletti C, Galbardi B, Kapetis D, Vattemi G, Guglielmi V, Tonin P, Salerno F, Morandi L, Tomelleri G, Mantegazza R, Bernasconi P. Autophagy, inflammation and innate immunity in inflammatory myopathies. PLoS One 9(11):e111490, 2014.
13. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 137(1-2):125-133, 2003.
14. Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol 18(3):331-344, 2004.
15. De Mori R, Straino S, Di Carlo A, Mangoni A, Pompilio G, Palumbo R, Bianchi ME, Capogrossi MC, Germani A. Multiple effects of high mobility group box protein 1 in skeletal muscle regeneration. Arterioscler Thromb Vasc Biol 27(11):2377-2383, 2007.
16. Dorph C, Englund P, Nennesmo I, Lundberg IE. Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. Ann Rheum Dis 65(12):1565-1571, 2006.
17. Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, Nennesmo I, Malmberg KJ, Soderberg-Naucler C, Trollmo C, Lundberg IE, Malmstrom V. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 183(7):4792-4799, 2009.
18. Fernandez I, Harlow L, Zang Y, Liu-Bryan R, Ridgway WM, Clemens PR, Ascherman DP. Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis. J Immunol 191(4):1865-1872, 2013.
19. Fujiyama T, Ito T, Ogawa N, Suda T, Tokura Y, Hashizume H. Preferential infiltration of interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis. Clin Exp Immunol 177(1):110-120, 2014.
20. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 41(3):414-421, 2014.
21. Greenberg SA. Type 1 interferons and myositis. Arthritis Res Ther 12(Suppl 1):S4, 2010.
22. Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, Bregoli L, O'connor KC, Amato AA. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65(11):1782-1787, 2005.
23. Greenberg SA, Higgs BW, Morehouse C, Walsh RJ, Kong SW, Brohawn P, Zhu W, Amato A, Salajegheh M, White B, Kiener PA, Jallal B, Yao Y. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun 13(3):207-213, 2012.
24. Grundtman C, Bruton J, Yamada T, Ostberg T, Pisetsky DS, Harris HE, Andersson U, Lundberg IE, Westerblad H. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 24(2):570-578, 2010.
25. Guo X, Higgs BW, Rebelatto M, Zhu W, Greth W, Yao Y, Roskos LK, White WI. Suppression of soluble T cell-associated proteins by an anti-interferon-alpha monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford, England) 53(4):686-695, 2014.
26. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 8(4):195-202, 2012.
27. Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, Rebelatto M, Le C, Amato A, Fiorentino D, Greenberg SA, Drappa J, Richman L, Greth W, Jallal B, Yao Y. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73(1):256-262, 2014.
28. Hirakata M. Autoantibodies to aminoacyl-tRNA synthetases. Intern Med 44(6):527-528, 2005.
29. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, Casciola-Rosen L, Hartlein M, Kron M, Yang D, Yiadom K, Dwivedi S, Plotz PH, Oppenheim JJ. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 196(6):781-791, 2002.
30. Ji SQ, Neustrom S, Willis GM, Spurlock ME. Proinflammatory cytokines regulate myogenic cell proliferation and fusion but have no impact on myotube protein metabolism or stress protein expression. J Interferon Cytokine Res 18(10):879-888, 1998a.
31. Ji SQ, Neustrom S, Willis GM, Spurlock ME. Proinflammatory cytokines regulate myogenic cell proliferation and fusion but have no impact on myotube protein metabolism or stress protein expression. J Interf Cytok Res 18(10):879-888, 1998b.
32. Kawai T, Akira S. TLR signaling. Cell Death Differ 13(5):816-825, 2006.
33. Kenna TJ, Brown MA. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat Rev Rheumatol 9(6):375-379, 2013.
34. Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, Kim DS, Baek SH, Lee SH, Lee JH, Kim HY, Kim SI. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol 29(3):273-279, 2010.
35. Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, Sumita Y, Yamaguchi S. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford, England) 53(10), 2014.
36. Kovacs JR, Li C, Yang Q, Li G, Garcia IG, Ju S, Roodman DG, Windle JJ, Zhang X, Lu B. Autophagy promotes T-cell survival through degradation of proteins of the cell death machinery. Cell Death Differ 19(1):144-152, 2012.
37. Krystufkova O, Barbasso Helmers S, Venalis P, Malmstrom V, Lindroos E, Vencovsky J, Lundberg IE. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res Ther 16(5):454, 2014.
38. Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF. Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24(1):73-79, 1998.
39. Loell I, Pandya J, Raghvan S, Zong M, Malmstrom V, Lundberg IE. Persisting CD28null T cells, but not regulatory T cells, in muscle tissue of myositis patients after immunosuppressive therapy. Ann Rheum Dis 71(Suppl 1):A44, 2012.
40. Lopez De Padilla CM, Mcnallan KT, Crowson CS, Bilgic H, Bram RJ, Hein MS, Ytterberg SR, Amin S, Peterson EJ, Baechler EC, Reed AM. BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies. J Rheumatol 40(3):294-302, 2013.
41. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 63(1):9-16, 1995.
42. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 7(6):343-354, 2011.
43. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9(6):641-649, 2008.
44. Moran EM, Heydrich R, Ng CT, Saber TP, Mccormick J, Sieper J, Appel H, Fearon U, Veale DJ. IL-17A expression is localised to both mononuclear and polymorphonuclear synovial cell infiltrates. PLoS One 6(8):e24048, 2011.
45. Moran EM, Mastaglia FL. The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul Disord 24(11):943-952, 2014.
46. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, Chang J, Dwivedi S, Mitsak M, Chen YW, Plotz P, Rosen A, Hoffman E, Raben N. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 52(6):1824-1835, 2005.
47. Nagaraju K, Casciola-Rosen L, Rosen A, Thompson C, Loeffler L, Parker T, Danning C, Rochon PJ, Gillespie J, Plotz P. The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 164(10):5459-5465, 2000.
48. Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford, England) 50(7):1344-1346, 2011.
49. Nyberg P, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 27(4):940-948, 2000.
50. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 141(5):1543-1549, 1988.
51. Peng QL, Shu XM, Wang DX, Wang Y, Lu X, Wang GC. B-cell activating factor as a serological biomarker for polymyositis and dermatomyositis. Biomark Med 8(3):395-403, 2014.
52. Rayavarapu S, Coley W, Kinder T, Nagaraju K. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skeletal Muscle 3(1):13, 2013a.
53. Rayavarapu S, Coley W, Van Der Meulen JH, Cakir E, Tappeta K, Kinder TB, Dillingham BC, Brown KJ, Hathout Y, Nagaraju K. Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target. Arthritis Rheum 65(12):3248-3258, 2013b.
54. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic cells. J Biol Chem 276(40):37692-37699, 2001.
55. Ritchlin C, Rahman P, Kavanaugh A, Mcinnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990-999, 2014.
56. Sallum AM, Kiss MH, Silva CA, Wakamatsu A, Vianna MA, Sachetti S, Marie SK. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 5(2):93-100, 2006a.
57. Sallum AM, Kiss MH, Silva CaA, Wakamatsu A, Vianna MaA, Sachetti S, Marie SK. Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. Autoimmun Rev 5(2):93-100, 2006b.
58. Schmidt D, Martens PB, Weyand CM, Goronzy JJ. The repertoire of CD4+ CD28-T cells in rheumatoid arthritis. Mol Med 2(5):608-618, 1996.
59. Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 176(1-2):9-15, 2006.
60. Stephenson LM, Miller BC, Ng A, Eisenberg J, Zhao Z, Cadwell K, Graham DB, Mizushima NN, Xavier R, Virgin HW, Swat W. Identification of Atg5-dependent transcriptional changes and increases in mitochondrial mass in Atg5-deficient T lymphocytes. Autophagy 5(5):625-635, 2009.
61. Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55(3):342-347, 1996.
62. Thaçi D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, Gong Y, Papavassilis C; The STATURE study group. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol, epub ahead of print, Mar. 30, 2015.
63. Tournadre A, Lenief V, Eljaafari A, Miossec P. Immature muscle precursors are a source of interferon-beta in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 64(2):533-541, 2012.
64. Tournadre A, Lenief V, Miossec P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 62(7):2144-2151, 2010.
65. Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, Lundberg IE. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 50(5):1586-1594, 2004.
66. Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J Immunol 165(11):6301-6307, 2000.
67. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2):179-189, 2006.
68. Venalis P, Pandya J, Stache V, Nader G, Malmstrom V, Lundberg IE, Fasth A. CD28null T cells from myositis patients are cytotoxic to autologous muscle cells in vitro. Arthritis Rheum 63(10):S323-S324, 2011.
69. Vezzoli M, Castellani P, Corna G, Castiglioni A, Bosurgi L, Monno A, Brunelli S, Manfredi AA, Rubartelli A, Rovere-Querini P. High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal 15(8):2161-2174, 2011.
70. Yokota M, Suzuki K, Tokoyoda K, Meguro K, Hosokawa J, Tanaka S, Ikeda K, Mikata T, Nakayama T, Kohsaka H, Nakajima H. Roles of mast cells in the pathogenesis of inflammatory myopathy. Arthritis Res Ther 16(2):R72, 2013.
71. Zong M, Bruton JD, Grundtman C, Yang H, Li JH, Alexanderson H, Palmblad K, Andersson U, Harris HE, Lundberg IE, Westerblad H. TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 72(8):1390-1399, 2013.
72. Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, Barbasso Helmers S, Nennesmo I, Malmstrom V, Lundberg IE. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis 73(5):913-920, 2014a.
73. Zong M, Jörholt J, Winter J, Lindroos E, Harris HE, Lundberg IE. A8.24 autophagy may contribute to glucocorticoid resistance in myositis patients by maitaining muscle T cells homeostasis. Ann Rheum Dis 73(Suppl 1):A85-A86, 2014b.
74. Zong M, Loell I, Lindroos E, Nader GA, Alexanderson H, Hallengren CS, Borg K, Arnardottir S, Mcinnes IB, Lundberg IE. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor alpha expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 71(6):1055-1063, 2012b.